Premium
Effects of peroxisome proliferator‐activated receptor‐α and ‐γ agonist, JTT‐501, on diabetic complications in Zucker diabetic fatty rats
Author(s) -
Shibata Tsutomu,
Takeuchi Satomi,
Yokota Seiko,
Kakimoto Kochi,
Yonemori Fumihiko,
Wakitani Korekiyo
Publication year - 2000
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0703328
Subject(s) - troglitazone , medicine , endocrinology , diabetes mellitus , agonist , rosiglitazone , peroxisome proliferator activated receptor , type 2 diabetes , receptor
This study has investigated the effects of JTT‐501, a peroxisome proliferator‐activated receptor (PPAR)‐α and PPAR‐γ agonist, on the pathogenesis of diabetic complications in the Zucker diabetic fatty (ZDF) rats, a model of type 2 diabetes. Comparison is made with troglitazone, a PPAR‐γ agonist. The ZDF rats exhibited hyperglycaemia and hyperlipidaemia, and developed diabetic complications such as cataract, nephropathy, and neuropathy. Treatment with JTT‐501 from the prediabetic stage controlled glycaemia and lipidaemia, and prevented the development of diabetic complications. Troglitazone was less effective in controlling serum cholesterol and neuropathy. ZDF rats developed diabetic osteopenia with reduced bone turnover, and this was prevented by JTT‐501 and troglitazone, possibly mediated by increased bone turnover and bone formation. Since JTT‐501 controlled glycaemia and lipidaemia in ZDF rats and prevented several diabetic complications, it is suggested that treatment with JTT‐501, which activates both PPAR‐α and PPAR‐γ, could provide a valuable therapeutic approach against diabetic complications in type 2 diabetes.British Journal of Pharmacology (2000) 130 , 495–504; doi: 10.1038/sj.bjp.0703328